Understand the source comparison
SS-31 Barth Syndrome: Mechanisms vs Standard Heart Failure Management
SS-31 (Elamipretide) Cardiolipin stabilization at inner mitochondrial membrane; restores cristae structure Directly addresses defect. Improves ATP production and reduces ROS generation Improved 6-minute walk distance (mean +46m in TAZPOWER), modest LVEF improv
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- SS-31 (Elamipretide)
- Cardiolipin stabilization at inner mitochondrial membrane; restores cristae structure
- Directly addresses defect. Improves ATP production and reduces ROS generation
- Improved 6-minute walk distance (mean +46m in TAZPOWER), modest LVEF improvement, reduced fatigue
- Does not correct TAZ mutation; long-term efficacy beyond 12 weeks unknown
- First therapy to address root mitochondrial structural failure rather than downstream symptoms
- ACE Inhibitors / ARBs
- Reduce afterload and ventricular remodeling through renin-angiotensin-aldosterone blockade
- None. Symptomatic management only
- Slower progression of heart failure symptoms
- Does not improve mitochondrial ATP production or oxidative capacity
- Standard of care for cardiomyopathy but insufficient as monotherapy in Barth syndrome
- Beta-Blockers
- Reduce heart rate and myocardial oxygen demand
- Reduced risk of arrhythmia and sudden cardiac death
- May worsen exercise intolerance in patients already limited by oxidative capacity
- Necessary for arrhythmia management but does not address energy deficit
- Coenzyme Q10 Supplementation
- Electron carrier in respiratory chain
- Marginal. Only effective if CoQ10 deficiency exists, not structural defect
- Limited evidence in Barth syndrome; inconsistent results in trials
- Does not stabilize cardiolipin or restore cristae structure
- Commonly used but mechanistically mismatched to the cardiolipin defect
- L-Carnitine Supplementation
- Facilitates long-chain fatty acid transport into mitochondria
- None in Barth syndrome. Substrate transport is not the limiting factor
- No consistent benefit in Barth-specific studies
- Addresses wrong step in energy metabolism pathway
- Frequently prescribed but lacks evidence in cardiolipin-deficient states
- Heart Transplantation
- Complete replacement of failing myocardium
- Eliminates defective mitochondria but does not address skeletal muscle or systemic manifestations
- Only curative option for end-stage cardiac failure
- Does not treat neutropenia, growth delay, or skeletal myopathy; recurrence risk in donor heart unclear
- Last resort when medical management fails. Does not address multi-system mitochondrial dysfunction
- SS-31 is the only intervention in this table that targets the cardiolipin defect directly. Every other therapy manages symptoms downstream of the mitochondrial failure. Reducing workload on a failing heart, supplementing cofactors that aren't actually deficient, or replacing the organ entirely. None of them restore the ability of cardiac myocytes to produce ATP efficiently, which is why Barth syndrome patients continue to decline on standard heart failure regimens. The TAZPOWER trial's 46-meter improvement in 6-minute walk distance may sound modest, but in a population where baseline exercise capacity is 50–60% of predicted and most patients cannot climb a flight of stairs without stopping, it represents a meaningful restoration of functional independence.